FDA drug recalls

Formal FDA enforcement reports for prescription and over-the-counter drugs — contamination, wrong potency, mislabeling, and manufacturing failures. 341 recalls in the last 12 months, in plain English.

Recent recalls

Page 2 of 12
  • Greenwich Rx glutathione injection recalled for microbial contamination

    Greenwich Rx is recalling 4,319 vials of its 200 mg/mL glutathione injection (10 mL multi-dose vials, for subcutaneous use only) because they may be contaminated with microbes. The recall covers 12 lots with beyond-use dates from October 2 to November 26, 2026, distributed nationwide. No injuries have been reported.

    SeriousFDAOct 27, 2026Greenwich Rx

  • Par Argatroban injection recalled for particulate matter

    Par Health USA's Argatroban Injection vials contain unwanted particles—including cellulose, polystyrene, plastic, stainless steel, or rubber stopper material—in the solution. The contamination affects multiple lot numbers distributed nationwide. No injuries have been reported.

    SeriousFDAOct 26, 2026Paragon 282 products

  • ValuHealth acetaminophen 500 mg recalled for incorrect inner label

    ValuHealth Extra Strength Pain Relief Acetaminophen 500 mg bottles have an incorrect label on the bottle itself. The outer carton correctly says "Acetaminophen 500 mg," but the label on the bottle says "Pain Relief PM" — a different product. This mismatch could cause confusion about what you're taking.

    ModerateFDAOct 26, 2026Prodose

  • GSMS lubricant eye drops recalled for polyethylene-related impurities

    GSMS Incorporated is recalling 30-count packs of Carboxymethylcellulose Sodium 0.5% Lubricant Eye Drops (NDC 51407-945-30), made by Huons Co., Ltd. in South Korea. Testing detected polyethylene (PE)-related oligomers, so the product failed its impurities and degradation specification. No injuries have been reported.

    ModerateFDAOct 26, 2026Huons

  • Strides Pharma cinacalcet tablets recalled for failed dissolution

    Strides Pharma is recalling one lot of Cinacalcet 30 mg tablets because they failed to meet dissolution specifications, meaning the tablets may not break down properly in the body. This could result in inconsistent or reduced drug effectiveness. The affected lot is 7717825A, expiring 11/30/2028.

    ModerateFDAOct 26, 2026Strides

  • Macleods Pharma blood pressure tablets recalled for failed dissolution

    Macleods Pharma USA is recalling specific lots of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide combination tablets (40 mg/10 mg/12.5 mg) because they failed to meet dissolution specifications. This means the tablets may not break down properly in the body, potentially reducing how well the medication works.

    ModerateFDAOct 26, 2026MacLeods Pharma

  • Abirtega abiraterone acetate recalled for failed weight uniformity

    Hikma Pharmaceuticals is recalling Abirtega (abiraterone acetate) 250 mg tablets due to failed weight uniformity specifications. Lot 3047 (expiring July 2027) does not meet quality standards. The issue was identified during quality testing; no injuries have been reported.

    ModerateFDAOct 23, 2026Hikma Pharmaceuticals

  • Safecor Health metoclopramide tablets recalled for co-mingling

    Safecor Health is recalling specific batches of metoclopramide 5 mg tablets manufactured for Teva Pharmaceuticals due to co-mingled tablets in the bottles. Co-mingling means tablets from different batches or products may have been mixed together. The affected lot is 3116509 with an expiry date of 07/31/2027.

    ModerateFDAOct 23, 2026Safecor Health

  • Glenmark abiraterone acetate tablets recalled for labeling problem

    Glenmark Pharmaceuticals is recalling Abiraterone Acetate Tablets USP 500 mg in 60-count bottles due to a labeling defect. The affected lot (13250135, expiring 11/2027) was distributed nationwide. No injuries have been reported.

    ModerateFDAOct 23, 2026Glenmark

  • Ritedose Formoterol Fumarate inhalation solution recalled for impurity concerns

    Ritedose Pharmaceuticals recalled one lot of Formoterol Fumarate Inhalation Solution (20mcg/2mL) because it failed quality testing for impurities and degradation. The affected lot (25BL0, expiring 02/28/2027) was distributed nationwide. No injuries have been reported.

    ModerateFDAOct 23, 2026Ritedose

  • Par Health dexmedetomidine injection recalled for particulate matter

    Par Health USA's Dexmedetomidine HCl injection vials contain unwanted particulate matter, identified as cellulose or stopper material. The contamination affects two specific lots distributed nationwide. This is a prescription medication used during anesthesia and sedation.

    SeriousFDAOct 21, 2026Paragon 28

  • American Health Packaging metoclopramide recalled for foreign tablets

    American Health Packaging distributed metoclopramide 5 mg tablets that contained foreign tablets or capsules mixed in with the correct medication. The contamination was found in two lot numbers distributed nationwide. No injuries have been reported.

    ModerateFDAOct 21, 2026American Health Packaging

  • Houston Rx tirzepatide and sermorelin vials recalled for sterility concerns

    Houston Rx is recalling two injectable products, a tirzepatide/niacinamide 2 mL vial and a sermorelin 10 mL vial, because the company cannot assure they are sterile. The recall covers 71 vials distributed nationwide in the USA, and the FDA has reported no injuries.

    ModerateFDAOct 21, 2026Houston Rx2 products

  • Zydus Hydrocortisone Sodium Succinate injection recalled for impurity concerns

    Zydus Pharmaceuticals is recalling specific lots of Hydrocortisone Sodium Succinate for Injection because the drug failed quality testing for impurities and degradation. The affected lots (LB00047A and LB00048A, expiring 03/2028) were distributed nationwide. No injuries have been reported.

    ModerateFDAOct 21, 2026Zydus

  • Teva metoclopramide tablets recalled for foreign tablets or capsules

    Teva Pharmaceuticals discovered that some bottles of Metoclopramide 5 mg tablets contain foreign tablets or capsules mixed in with the correct medication. The contamination was found in specific lots distributed nationwide. No injuries have been reported.

    ModerateFDAOct 21, 2026Teva

  • WAP Sensual Enhancement Capsules recalled for undeclared drugs

    WAP Sensual Enhancement Capsules were sold without FDA approval and contain three undeclared prescription medications: sildenafil, tadalafil, and flibanserin. These are potent drugs that require a doctor's prescription and can cause serious health problems, especially in people taking other medications or with certain medical conditions.

    SeriousFDAOct 20, 2026Erotic Enhancers

  • Right Value Drug Stores testosterone cypionate recalled for sterility risk

    Right Value Drug Stores LLC is recalling compounded testosterone cypionate injection (200 mg/mL) in 5 mL and 30 mL vials due to lack of sterility assurance. The affected vials were distributed nationwide to medical offices. No injuries have been reported.

    ModerateFDAOct 19, 2026Right Value Drug Stores LLC

  • Barbie, Hot Wheels and more toothpaste recalled for manufacturing issues

    Ashtel Studios Inc. of Ontario, California is recalling 17 fluoride toothpaste products nationwide because they were made in ways that did not meet FDA manufacturing standards. The products are sold under the Barbie, Hot Wheels, Crayola and My Little Pony names, plus the Brush Buddies, evo, ARU and BB brands. No injuries have been reported.

    ModerateFDAOct 19, 2026PRITAM INTERNATIONAL PRIVATE LIMITED17 products

  • Pfizer Levoxyl 175 mcg tablets recalled for reduced potency

    Pfizer is recalling specific lots of Levoxyl (levothyroxine sodium) 175 mcg tablets because stability testing found the drug potency fell below required specifications. This means some tablets may contain less active medication than labeled. The recall affects 134 bottles with lot number 24W07, expiring 11/30/2026.

    ModerateFDAOct 16, 2026Pfizer2 products

  • Hepalink Heparin Sodium Injection recalled for sterility concerns

    Hepalink USA is recalling Heparin Sodium Injection (5,000 USP Units/mL) due to lack of assurance that the product is sterile. The affected multidose vials have lot number CU03232A with an expiration date of January 31, 2028. This product is used in hospitals and medical settings.

    ModerateFDAOct 16, 2026Techdow

  • Viatris telmisartan and amlodipine tablets recalled for potential superpotency

    Certain lots of Telmisartan and Amlodipine 40mg/5mg tablets manufactured by Mylan Pharmaceuticals (Viatris) may contain higher-than-specified amounts of Telmisartan, the blood pressure-lowering active ingredient. The affected lots were distributed nationwide. No injuries have been reported.

    ModerateFDAOct 16, 2026Viatris

  • Ascend amlodipine and olmesartan tablets recalled for dissolution failure

    Ascend Laboratories is recalling one lot of amlodipine and olmesartan medoxomil combination tablets (10mg/40mg) because they do not dissolve properly in the body. This means the medication may not work as intended. The affected lot was distributed nationwide.

    ModerateFDAOct 16, 2026Ascend Laboratories

  • Orbi 20 and Omni Gold creams recalled for mercury contamination

    DANALVIG LLC is recalling two skin whitening creams, Orbi 20 Whitening Cream and Omni Gold Anti-Marks Cream Extra Brightening, sold nationwide through eBay. FDA analysis found the products contain mercury, and both are made by White Gold International in Lahore, Pakistan. No injuries have been reported.

    SeriousFDAOct 14, 2026DANALVIG LLC2 products

  • Apothecary Pharma tirzepatide and NAD+ injections recalled over sterility

    Apothecary Pharma is recalling two sterile injection vials because the company cannot assure they are sterile. The recall covers 22 vials of Tirzepatide Injection 18 mg/mL (4 mL multi-dose vial) and 1 vial of Apothecary NAD+ Injection 200 mg/mL (6 mL multi-dose vial), distributed nationwide. No injuries have been reported.

    ModerateFDAOct 14, 2026Apothecary Pharma2 products

  • Taro and Northstar Rx tretinoin cream recalled for impurities

    Sun Pharmaceutical is recalling three tretinoin cream USP 0.05% products, sold in 45 g and 20 g tubes under the Taro and Northstar Rx names. The cream failed the FDA's impurity and degradation standards. No injuries have been reported.

    ModerateFDAOct 14, 2026Sun Pharmaceutical3 products

  • Carolina Infusion compounded injectables recalled for sterility risk

    Carolina Infusion LLC of Ridgeland, SC, is recalling 16 compounded injectable products sold as tirzepatide, semaglutide, semaglutide/cyanocobalamin, tirzepatide/cyanocobalamin, sermorelin, Quad-Mix, and Tri-MIX. The company cannot assure that the products are sterile, which relates to the bacteriostatic water used in the formulation and the processing equipment. No injuries have been reported.

    ModerateFDAOct 14, 2026Carolina Infusion16 products

  • J&J IMAAVY injection recalled for particulate matter

    A single lot of IMAAVY (nipocalimab-aahu) injection contains particulate matter that should not be present in the medication. This affects 49 vials distributed in Ohio. The contamination was detected before the medication reached patients.

    ModerateFDAOct 14, 2026Johnson & Johnson

  • Cipla USA fosfomycin granules recalled for failed impurity specifications

    Cipla USA is recalling one lot of Fosfomycin Tromethamine Granules for Oral Solution due to failed quality testing for impurities and degradation. The affected lot (5KA0405, expiring 12/31/2026) was distributed nationwide. No injuries have been reported.

    ModerateFDAOct 14, 2026Cipla

  • Preferred Pharmaceuticals Lidocaine Ointment recalled for content uniformity failure

    Preferred Pharmaceuticals' Lidocaine Ointment USP 5% (generic Xylocaine) in 50 g jars failed to meet content uniformity specifications, meaning the active ingredient may not be evenly distributed throughout the product. This affects four specific lots with expiration dates of April 30, 2027. No injuries have been reported.

    ModerateFDAOct 14, 2026Preferred Pharmaceuticals

  • BioSpectra Tris/Tromethamine API recalled for stability failure

    BioSpectra, Inc. is recalling one lot of Tris/Tromethamine, USP, GMP, API Grade manufactured at its Bangor, Pennsylvania facility. The affected lot failed stability testing specifications required for pharmaceutical-grade active ingredients.

    ModerateFDAOct 14, 2026BioSpectra

Explore other recall topics